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Summary An epthelial cell surface antigen is described which is defined by monoclonal antibody HEA125
(IgGI). The antibody was raised against the colon carcinoma cell line HT-29. Under reducing conditions
HEA125 immunoprecipitates a surface glycoprotein of Mr 34,000 which was designated Egp34. The antigen
does not contain disulfide-linked subunits. A slightly different migration behavior under non-reducing
conditions (Mr 39,000) may be due to intrachain disulfide bonds. After enzymatic cleavage of N-linked
carbohydrate residues the apparent molecular weight of the antigen was 29,000. Egp34 is a major cell surface
component of HT-29 cells (106 molecules per cell). No antigen could be detected in the sera of colorectal
cancer patients. A panel of malignant cell lines and normal cells was studied for surface expression of the
antigen. 17/17 carcinoma lines of 6 different origins expressed the antigen, whereas 16/16 melanoma,
neuroblastoma, sarcoma and lymphoma/leukaemia were unreactive as it was the case for normal fibroblasts
and blood cells. Immunoperoxidase staining of frozen tissue sections with HEA125 demonstrated the presence
of Egp34 in almost all normal epithelia and tumours derived therefrom. No reactivity with non-epithelial
tissues was observed. Undifferentiated carcinomas of various origins homogeneously expressed Egp34.
Therefore, HEA125 may become a valuable tool for the immunohistochemical diagnosis of carcinoma.
Since the advent of hybridoma technology numerous efforts
have been made to generate monoclonal antibodies with
specificity for plasma membrane antigens of selelcted
epithelial cell types and their tumours (Koprowski et al.,
1972; Metzgar et al., 1982; Schmiegel et al., 1985; Togashi et
al., 1984; Colcher et al., 1981; Stacker et al., 1985; Bernal et
al., 1984; Reeve et al., 1985; Bast et al., 1981; Ueda et al.,
1981; Masuko et al., 1984; Frankel et al., 1982). Most
monoclonal antibodies (MAbs) to epithelial cell surface
components described so far recognize differentiation
antigens that i) are not specific for the malignant phenotype,
that ii) bind to the tumour cells of an individual carcinoma
with considerable heterogeneity, and that iii) are
undetectable in a subset of tumours of a given origin
(reviewed in Edwards, 1985).
In contrast to antigens with a restricted and heterogeneous
expression among human epithelial tumours, surface
antigens with wide distribution and homogeneous expression
in these neoplasms would be helpful in the diagnosis of
anaplastic carcinomas in immunocytochemistry and immuno-
histochemistry provided the antigens are expressed in a
strictly epithelium-specific manner. Antibodies to such antigens
would be suitable tools for staining and targeting of viable
carcinoma cells in vitro and in vivo. In the present
investigation we report on a monoclonal antibody that reacts
with a cell surface antigen of Mr 34,000 present on all
carcinoma cell lines tested, however, not on various cell lines
and normal cells of non-epithelial origin. Biochemical
characteristics of the antigen are described and the presence
of soluble antigen in sera of cancer patients is examined. An
immunohistological survey of human tissues demonstrates
the strong and homogeneous expression of the antigen in
most normal epithelial cell types and in carcinomas. An
epithelium-specific pattern of expression of the M, 34,000
antigen is also found in tissues.
Materials and methods
Cell lines and tissues
Cell lines of various tissue origins as indicated in Table I
were provided by the following institutions. From the
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American Type Culture Collection (Rockville, MD): WiDr,
SWI116, HeLa, T-24, Raji, Daudi, P3-HR1, HL-60, U-937
and K-562; from Drs J. Fogh and M. Pfreundschuh
(Memorial Sloan-Kettering Cancer Center, New York): HT-
29, SK-LU-1, SK-LC-LL, SK-MES-1, Calu-1, SK-N-SH,
HEp-2, ME-180, AlAb, PSA and F136-35-36. Several other
colleagues kindly donated their cell lines: ChaGo (Dr K.
Bosslet, Marburg, FRG); NCI-N417, SCLC-16H, SCLC-
22M (Dr G. Bepler, Marburg, FRG); SW210-5 (Dr F.
Herrmann, Boston, MA); MML-I, MML-III, MeWo (Dr W.
Tilgen, Heidelberg, FRG); JM-1, Jurkat, HSB-2 (Dr B.
Dorken, Heidelberg, FRG); LICR-LON-HMy-2 (Ludwig
Institute of Cancer Research, UK).
Suspension cell lines were grown in RPMI 1640 medium
completed with 10% heat-inactivated foetal calf serum,
2mM L-glutamine, 1 mM pyruvate, penicillin-streptomycin
100Uml-' (all components from Gibco, Karlsruhe, FRG).
Adherent cell lines were cultivated in complete RPMI 1640
supplemented with 50puM 2-mercaptoethanol, 1% (v/v) non-
essential amino acids (Seromed, Berlin, FRG) and 4IUI-
human insulin (Novo, Mainz, FRG). Cell lines were
mechanically harvested from monolayer cell cultures after
treatment with 0.25% EDTA, washed twice in RPMI 1640
and used for cell binding assays and immunizations.
P3X63Ag8.653 murine myeloma cells (Kearney et al., 1979)
were maintained in complete RPMI 1640 medium.
Specimens of normal and neoplastic tissues were obtained
from surgical material and snap-frozen in liquid nitrogen
within two hours after removal.
Immunization and hybridoma production
Female BALB/c mice were immunized by i.p. injection of
- 2 x 107 viable HT-29 cells. The mice were boosted four
times at four-week intervals with 1-2 x 107 HT-29 cells i.p.,
the last injection 3 days prior to the fusion experiment.
Fusions were performed essentially as described by Galfre
et al. (1977). Splenocytes from immune spleens and Ag8.653
myeloma cells were mixed at a cell ratio of 5: 1 and fused in
1.5ml of 45% polyethylene glycol 4000 (Merck, Darmstadt,
FRG) in Dulbecco's PBS (Seromed) with 5% dimethyl-
sulfoxide (Merck). After washing in Dulbecco's PBS, cells
were resuspended in warm HAT medium (RPMI 1640
medium containing 13.611 mgI 1 hypoxanthine, 0.176mgI -1
aminopterin and 3.876mgl-1 thymidine). Cells were
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distributed in 24-well microtiter plates (Costar, Cambridge,
MA) at 5 x l05 cells per well after preincubation for 48h
with 3 x 104 non-immune BALB/c peritoneal macrophages.
Hybrids were kept in HAT selection medium for 2 weeks.
On days 12 to 14 after fusion, supernatants from wells with
visible colonies were assayed for cell binding in the immuno-
enzymatic staining assay. Hybridomas of interest were
subcloned by limiting dilution on a feeder layer of BALB/c
spleen cells (5 x 105 cellsml-1).
Immunoenzymatic staining assay onfixed cells (ISA)
The test was essentially performed as described by Dorken et
al. (1986). Tissue culture cells in serum-free medium were
distributed in Terasaki microtiter plates (Falcon, Oxnard,
CA) at 3.3 x 103 cells per well pretreated overnight with
poly-L-lysine (100Mgml-1 in PBS; Sigma, St. Louis, MO).
Cells were fixed in 0.025% glutardialdehyde (Merck) for
10min at room temperature. Plates were washed with PBS,
blocked with PBS/0.2% gelatine (Merck)/0.1% NaN3 and
stored at 4°C.
For the immunostaining, cells were incubated with
hybridoma supernatants (5Ml/well) for 1 h at room tempera-
ture. After 3 washings with PBS/gelatine, biotinylated goat
anti-mouse Ig (Tago, Burlingame, CA) diluted 1:40 in
PBS/5% pooled human IgG (Behringwerke) and avidin-
peroxidase (Vector, Burlingame, CA) diluted 1:800 were
added for 30min each. Alternatively, a 4-step peroxidase
anti-peroxidase technique was used as described previously
(Momburg et al., 1986). After 4 washings the substrate
solution containing 0.4mgml-1 3-amino-9-ethylcarbazole
(Sigma), 5% dimethylformamide (Sigma) and 0.015% H202
in 0.1M acetate buffer (pH 5.2) was added for 10min. The
reaction (mostly ring-like stainings) was evaluated under a
light microscope and scored -, +, + +, + + + in com-
parison to appropriate negative and positive controls.
Immunoperoxidase staining ofcytocentrifugates and tissue
sections
HT-29 cells in culture medium were cytocentrifuged onto
glass slides, air-dried and fixed with acetone for 10min. The
cells were incubated with 0.005M, 0.01M and 0.05MNaIO4
(Merck) in PBS for 60min at room temperature prior to
staining with HEA125 as described below.
Frozen sections of 5gm thickness were thoroughly air-
dried and then acetone-fixed at room temperature for
10min. After rehydration with PBS the sections were
incubated for 60min with purified HEA125 at a
concentration of 10Igml-1. Subsequently, sections were
overlaid with rabbit anti-mouse Ig (produced by us) goat
anti-rabbit IgG (Tago) and rabbit peroxidase anti-peroxidase
complex (Dakopatts, Copenhagen, Denmark), each for
30min at room temperature. The sandwich reagents were
used at concentrations of 10pugml-1, 20ugml-1 and 1:50,
respectively. The peroxidase substrate solution (see above,
'ISA') was added for 10min. The sections were
counterstained with Harris' hematoxylin and mounted with
glycerol gelatine.
Immunoprecipitation
Viable HT-29 cells were radioiodinated by the lacto-
peroxidase method essentially as described by Goding (1980).
Usually, 107 cells (viability >95%) were radiolabelled with
0.5mCi 1251 (Amersham Buchler) and subsequently
solubilized in TBS (10mM Tris, 150mM NaCl, pH 7.4)
containing 1% Nonidet P-40 (NP-40; Fluka), 1 mM phenyl-
methylsulphonylfluoride (Sigma) and 0.03 TIUml-1
aprotinin (Sigma). The glycoprotein fraction was isolated by
a Lens culinaris lectin Sepharose-4B column (Pharmacia,
Uppsala, Sweden) (Haymann & Crumpton, 1972). Purified
glycoproteins were non-specifically precipitated by
incubation with Protein A-Sepharose 4B (Pharmacia). For
immunoprecipitation, 106 cpm of glycoproteins were
mixed with 10,ug purified MAb, 15pg affinity-purified rabbit
anti-mouse Ig and 20,pl Protein A-Sepharose 4B (50%
solution). After overnight incubation at 4°C with gentle
rotation, the adsorbent was washed and then boiled in
reducing or non-reducing sodium dodecylsulfate (SDS)
sample buffer. Samples were subjected to polyacrylamide
slab gel electrophoresis (SDS-PAGE) using a discontinuous
buffer system according to Laemmli (1970). Dried gels were
visualized by exposure to Kodak X-Omat XR-5 X-ray film
employing Cronex Lightning Plus intensifying screens. 14C-
methylated molecular weight markers were obtained from
Amersham Buchler (lysozyme, Mr 14,300; carbonic
anhydrase, M, 30,000; ovalbumin, M, 46,000; bovine serum
albumin, Mr 69,000; phosphorylase b, M, 92,500; myosin, Mr
200,000).
For endo F treatment the immunoprecipitate was boiled
5min in 30,ul 100mM Tris/HCl, pH8.0, containing 0.5%
SDS, 1% 2-mercaptoethanol and 10mM EDTA. After
centrifugation 3p1 10% NP-40 and 2,u1 endoglycosidase F
(0.048 U/ul; Boehringer, Mannheim, FRG) were added to
the supernatant. Incubation was for 2h at 37°C or overnight
at room temperature, respectively. Endo F digests were
analysed by SDS-PAGE in parallel with non-digested
controls.
Radiobinding assays
HEA125 was purified from ascites fluid by DEAE Affi-Gel
Blue (Biorad, Munic, FRG) chromatography (Bruck et al.,
1982). Radioiodination of MAb was performed by a slight
modification of the chloramine-T method (Greenwood et al.,
1963) using 1 mCi 1251-iodide (Amersham Buchler,
Braunschweig, FRG) per 100pg ofpurified MAb.
The radioimmunoassay on live cells (CRIA) was
performed in flexible PVC microtiter plates (Dynatech,
Plochingen, FRG). Tissue culture cells were diluted in
PBS/0.2% gelatine/5% pooled human IgG. 50p1/well of
target cell suspension containing 106 viable cells were mixed
with 125I-labelled HEA125 (2 x 106cpm in 100pl) and allowed
to react for 1 h at room temperature. After 3 washings the dried
plate was sliced and the radioactivity of each well was
determined in a gamma-counter. 125I-labelled irrelevant
mouse monoclonal antibody of IgGI subtype served as a
negative control.
For quantitative determination of antigen sites per cell
HT-29 cells were incubated with increasing amounts of 1251I
HEA125 in triplicates. MAb binding to target cells was
analysed in a Scatchard plot.
A double determinant RIA was performed with purified
HEA125 coated to the wells of an immunoassay plate
(2 gml-1 antibody in 0.05 M sodium carbonate buffer,
pH9.6, overnight at 4°C). Unspecific binding sites were
blocked with PBS/gelatine. Dried wells were incubated with
serum dilutions (1:2, 1:5, 1:10 in PBS/Tween), tumour cell
supernatants or tumour cell lysates overnight. After extensive
washing with PBS/Tween 125I-labelled rabbit antiserum to
HT-29 cells was added for 1 h. The rabbit antiserum reactive
with Egp34 was purified by Protein A-Sepharose 4B
(Pharmacia) prior to radioiodination by the chloramine-T
method.
Dot blot ofenzyme-treated lysates
HT-29 cells were lysed in extraction buffer (107 cells per
100u1 of 50mM Tris/HCI, pH7.5, with 5mM iodoacetamide
(Serva, Heidelberg, FRG), 2mM EDTA, 1% NP-40) in the
presence of proteinase inhibitors (see above) for all enzyme
treatments except pronase. Lysates (1.5 x 107 cells per
enzyme) were incubated overnight at 37°C with equal volumes
containing the following enzymes or PBS for control:
endoglycosidase F (0.25U in PBS+5% n-octyl-L-glucoside
(Sigma); endoglycosidase D (Boehringer), 0.012U in716 G. MOLDENHAUER et al.
PBS +5% n-octyl-L-glucoside; neuraminidase (Behringwerke,
Marburg, FRG), 0.1 U in PBS; pronase E (Serva), 1 mg
100PuI1 PBS. After brief boiling of the mixture, 20 ul
(-106 cells) were dotted onto nitrocellulose paper
(Schleicher & Schiill, Dassel, FRG). Additionally, glycolipids
isolated from colon carcinoma tissue by chloroform/
methanol extraction (Schwartz et al., 1985) were dotted.
Unspecific binding sites were blocked with PBS/2% BSA
for h. Filters were subsequently incubated with purified
HEA125 (10 gml-1) and peroxidase-conjugated goat anti-
mouse IgG +IgM antiserum diluted 1:1000 (Jackson,
Avondale, PA). Washings were done with PBS/Tween.
The binding of antibody was visualized with diamino-
benzidine (Fluka, Ulm, FRG) used at lmgml-1 in 0.05M
Tris/HC1 (pH 7.6) with 0.01% H202.
Results
Hybridoma production and initial screening
Monoclonal antibody HEA125 was selected out of 960
hybridoma cultures obtained in 4 fusions following
immunization with the human colon carcinoma cell line HT-
29. After testing for mouse immunoglobulin secretion by
ELISA the culture supernatants were initially screened in the
ISA on fixed cells. Twenty-eight hybridomas that recognized
each of the carcinoma lines HT-29, SK-LU-1 and HeLa but
neither the melanoma line MML-I, nor the lymphoma lines
Raji and JM-l were cloned by limiting dilution and further
characterized. MAb HEA125 was determined to be of the
IgGI, K isotype.
Reactivity with tumour cell lines and normal blood cells
Purified MAb HEA125 was screened on a panel of human
malignant cell lines, normal fibroblasts and peripheral blood
cells using the CRIA on viable cells or the ISA on fixed cells
as indicated in Table I. HEA125 bound to all carcinoma cell
lines tested, irrespective of the use of unfixed or
glutaraldehyde-fixed cells. A particularly strong reaction was
obtained with colon carcinoma and small cell lung
carcinoma cell lines. HEA125 did not significantly
discriminate between different histotypes of carcinoma, nor
did it show organ specificity. Figure 1 illustrates the strong
membrane staining of fixed ME-180 cervix carcinoma cells
by HEA125. By contrast, no reaction was found with any of
the non-carcinoma cell lines used, which were derived from
melanoma, neuroblastoma, sarcoma and leukaemia/
lymphoma of the B, T and myelomonocytic lineage.
Accordingly, no binding was found to normal lung fibro-
blasts, as it was the case for the cell types of normal
peripheral blood.
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Figure 1 Immunoperoxidase staining of glutardialdehyde-fixed
ME-180 cervix carcinoma cells with MAb HEA125. The strong
reaction with the cell surface results in ring-like stainings ( x 962).
Table I Binding of MAb HEA125 to human malignant cell lines and normal blood cells in
radioimmunoassay on live cells and immunoenzymatic staining assay on fixed cells
CRIA ISA CRIA ISA
Colon carcinoma Melanoma
HT-29 ++++ +++ MML-1 -
WiDr + + + MML-3
SWI116 + + + Mewo
Lung carcinoma Neuroblastoma
adenocarcinoma SK-N-SH
SK-LU-1 + + + + + Sarcoma
squamous cell ca. P5A
SK-LC-LL + + + + B cell lymphoma
SK-MES-1 + Raji
Calu-I + Daudi
large cell ca. P3-HR1
ChaGo + + + + LICR-LON-HMy-2 -
small cell ca. T cell lymphoma
NCI-N417 + +++ JM-1 -
SCLC-16H + + + + Jurkat
SCLC-22H + + + HSB-2 -
SW210-5 + + + + Molt-3 -
Breast carcinoma Myelocytic leukemia
AlAb + + + HL-60 -
Cervix carcinoma U-937
HeLa + + K-562
ME-180 + + + Normalfoetalfibroblasts
Larynx carcinoma F136-35-36
HEp-2 + + + + + Normal blood cells
Bladder carcinoma lymphocytes
T-24 + monocytes
granulocytes
erythrocytes A, B, 0
'CRIA reactions were scored -, 0-3 x control value obtained with irrelevant IgG1 MAb (c.v.); +, 3-
10 x c.v.; + +, 10-30 x c.v.; + + +, 30-100 x c.v.; + + + +, > 100 x c.v.; bISA stainings were scored -,
negative; +, weak; + +, intermediate; + + +, strong.EPITHELIAL SURFACE GLYCOPROTEIN EGP34 717
Tissue reactivities ofHEA125
With a few exceptions (e.g., hepatocytes, epidermal
keratinocytes) HEA125 is reactive with all normal epithelial
cell types examined so far, not, however, with any
mesothelial, nervous and lympho-reticular cell type, nor with
the constituents of connective tissue (Table II; Figure 2).
Carcinomas of 10 different origins were all homogeneously
stained in all tumour cells with the exception of squamous
cell carcinomas, two of which were even unreactive (Table
II). The tumour cells of anaplastic, diffusely infiltrating
carcinomas, e.g., of the stomach (Figure 2e) or the
mammary gland, were reliably detected. No reaction was
found in sarcomas, lymphomas and neurogenic tumours. A
more detailed analysis of the immunohistological binding
pattern is be given elsewhere (Momburg et al., 1987).
Antigen characterization
After surface radioiodination of HT-29 cells, glycoprotein
fractions were isolated, immunoprecipitated with MAb
HEA125 and analysed by sodium dodecylsulfate gel electro-
phoresis. In the presence of 2-mercaptoethanol a strongly
labelled band of -34kD was found (Figure 3). In addition,
Table II Tissue reactivities of HEA125
Normal cells
Epithelial cells in
Colon
Small intestine
Stomach
Foveolae
Glands
Pancreas
Liver
Hepatocytes
Bile ducts
Esophagus
Basal cells
Superficial cells
Salivary gland
Mammary gland
Thyroid gland
Epidermis
Trachea
Lung
Kidney
Urinary bladder
Prostate
Uterus
Mesothelial cells
(6)a + +b Nervous tissue cells
(5) + + Neurons
(5) + + Gial cells
Connective tissue cells
+1/- Fibrocytes
(3) + + Myocytes
(3) Adipocytes
- Chondrocytes
+ + Osteocytes
(1) Vascular endothelium
+ Bone marrow-derived cells
- Lymphocytes
(2) + + Monocytes
(5) + + Histiocytes
(3) + + Granulocytes
(3) - Erythrocytes
(2) + +
(4) ++
(3) + +
(1) ++
(1) ++
(3) ++
Neoplasms
Colorectal carcinoma
Stomach carcinoma
Pancreas carcinoma
Mammary carcinoma
Lung carcinoma
Squamous cell carcinoma
Renal cell carcinoma
Prostate carcinoma
Ovarian carcinoma
Thyroid carcinoma
Leiomyosarcoma
Rhabdomyosarcoma
Undifferentiated sarcoma
Non-Hodgkin's lymphoma
Hodgkin's lymphoma
Malignant melanoma
Meningioma
Glioblastoma
Astrocytoma
Neurinoma
20/20C
10/10
5/5
10/10
4/4
3/5
5/5
5/5
5/5
4/4
0/3
0/3
0/3
0/20
0/2
0/7
0/7
0/1
0/1
0/1
+ +
+ +
+ +
+ +
+ +
++-
+ +
+ +
+ +
a weaker band of 40kD was visible that varied in intensity
in different experiments (Figures 3 & 5). Under non-reducing
conditions a major 39kD band and a minor 43kD band
were obtained indicating that the antigen does not consist of
disulfide-bonded subunits (Figure 4). To further study the
nature of the antigen, HEA125 precipitates from HT-29
lysate were treated with endoglycosidase F which cleaves off
N-linked carbohydrate residues. After Endo F treatment, the
strongly labelled 34kD band was shifted to 29kD (Figure 5),
the weaker 40kD band was reduced to a molecular weight
of 36kD. Based on its biochemical properties the antigen
was designated Egp (epithelial glycoprotein) 34.
Characterization ofthe determinant detected by HEA125
To study whether the epitope recognized is located on the
protein core or the carbohydrate moieties of Egp34, HT-29
lysates were treated with glycosidases (neuraminidase,
endoglycosidase D, endoglycosidase F) and pronase E,
dotted onto nitrocellulose and incubated with HEA125
(Figure 6). Binding was visualized using the indirect
peroxidase technique. Pronase E led to complete abrogation
of the staining, whereas the glycosidases did not significantly
influence the reaction. HEA125 did not react with a
glycolipid fraction isolated from colon carcinoma tissue. The
glycolipid dot was stained by a control MAb (HEA164) to
blood group carbohydrate antigens Lea and Leb, whose
reactivity was not affected by pronase E.
Additionally, HT-29 cytocentrifugates were incubated with
periodate prior to staining with MAb HEA125. One hour
pre-treatment with 0.05 M periodate did not reduce the
staining intensity while the reaction of a control MAb
HEA164 was entirely abolished (not shown). Taken together,
these results clearly indicate the protein nature of the epitope
recognized.
High binding values of MAb HEA125 in the radio-
immunoassay on viable cells indicated abundant presence of
Egp34 on the plasma membrane of HT-29 and several other
carcinoma cells. 125I-labelled HEA125 was titrated on HT-29
cellsinCRIAandthedataanalysedinaScatchardplot(Figure7).
Based on the condition that the molar ratio ofEgp34 to bound
1251-HEA125is 1.0,whichistheminimalassumption,Egp34was
found to beexpressed on the surface in a copy number ashigh as
1 x 106 per cell. The dissociation constant of HEA125 was
determined as 2.2 x 10-9 M.
Absence ofEgp34from the serum
Since several tumour-associated antigens, e.g. carcino-
embryonic antigen, are detectable in sera or other body
fluids of cancer patients in elevated amounts, we analysed
sera of colorectal cancer patients for the presence of soluble
Egp34.
We were not able to detect Egp34 in NP-40 lysates of HT-
29 cells when HEA125 was used both as the catcher and
detector antibody in a sandwich radioimmunoassay indicating
that the Egp34 molecule carries only one HEA125 epitope.
Therefore, in a solid phase RIA HEA125 was employed as
the catcher and radiolabeled, purified rabbit antibodies to
HT-29 cells as the detector (Table III). The purified rabbit
antiserum to HT-29 cells was shown to partially block the
binding of HEA125, thus containing a considerable
proportion of antibodies reactive with Egp34 (data not
shown). In lysate dilutions of HT-29 cells Egp34 was now
clearly detectable, lysate dilutions of the B cell line Raji
yielded background values. A strong binding was obtained
with 10 times concentrated supernatants of HT-29, SW 1116
and WiDr cells whereas with supernatants of antigen-
negative Raji, HSB-2 and HL-60 cells no specific binding
was observed. In this double determinant RIA pairs of pre-
and postoperative sera from 7 colorectal cancer patients,
preoperative sera from 12 further colorectal cancer patients
aNumber of specimens tested; bStaining intensity: + +, strong; +,
weak to intermediate; +/-, subset of cells positive; -, negative;
CNumber of tumour positive for HEA125/number of tumours tested.718 G. MOLDENHAUER et al.
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Figure 2 Immunoperoxidase staining of frozen tissue sections with MAb HEA125 (bars represent 100pm). Strong staining of all
epithelial cells in normal colon mucosa (a), normal prostate (b) and normal thyroid gland (c). (d) Endometrial glands during
secretory phase, note the basolateral membrane reaction of epithelial cells. (e) Disseminated tumour cells of a diffusely infiltrating
gastric carcinoma are strongly labelled by HEA125. (f) Plasma membrane staining of the tumour cells of a ductal invasive
mammary carcinoma.
and 6 normal sera were assayed at three dilutions. Only 1
preoperative serum yielded a twofold background value, the
remainder showed no significant binding.
Discussion
The study describes the production and characterization of a
monoclonal antibody directed against an antigen present on
continuously cultivated carcinoma cells of all origins and
histotypes tested so far, while not being present on
lymphoma, melanoma, sarcoma or neuroblastoma cell lines.
An immunohistochemical analysis revealed a very broad
distribution of the antigen on normal and neoplastic
epithelial cells. Only on a limited number of normal
epithelial cell types, e.g., hepatocytes, epidermal keratino-
cytes, and some squamous cell carcinomas Egp34 was not
detectable. An analysis of 98 tumours including 25 non-
epithelial neoplasms confirmed the specificity of HEA125
for the epithelial lineage.
MAb HEA125 raised to the colon carcinoma line HT-29
recognizes a glycoprotein which is abundantly expressed on
the cell surface of various carcinoma cells. One million
binding sites of HEA125 were determined in a Scatchard
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Figure 3 Immunoprecipitates from 1251I-labelled HT-29 lysates
run under reducing conditions. A, molecular weight markers; B,
HEA125; C, B-cell-specific control MAb (HD39); D, control
MAb to HLA-A, B, C (W6/32).
plot analysis on HT-29 cells. This number may represent an
unusually high expression as judged by the RIA binding
values obtained with other carcinoma lines. However, in
several carcinoma lines the glycoprotein defined by HEA125
seems to be a major constituent of the plasma membrane.
The biological significance of this finding still has to be
elucidated. It was shown that HEA125 reacts with the
protein core of a 34 kD glycoprotein which apparently does
not consist of disulfide-linked subunits. The slightly different
migration behaviour of the molecule in SDS-PAGE under
reducing or non-reducing conditions can be explained by
intrachain disulfide bond(s), the cleavage of which leads to
an increased mobility in SDS-PAGE. An additional, much
fainter band of 40kD (under reducing conditions) was
precipitated from HT-29 which can be accounted for by
differential glycosilation of the core protein. Additional
carbohydrates in the 40kD molecule are presumably 0-
linked since enzymatic cleavage of N-linked carbohydrates
did not shift the molecular weight to 29kD as obtained with
the major 34kD molecule, but only to 36kD. 2D-gel-
A B C D
Figure 4 SDS-PAGE under non-reducing conditions of
immunoprecipitates from 1251-labelled HT-29 lysates. A,
HEA125; B, negative control MAb (HD39); C, positive control
MAb (W6/32); D, molecular weight standards.
analysis and peptide mapping might help to clarify the
relationship of the two bands.
A number of investigators have described monoclonal
antibodies to carcinoma-associated surface antigens with
molecular weights similar to Egp34. Herlyn et al. (1984)
reported on a MAb, GA733, raised to the gastric carcinoma
line KATO-III which is broadly reactive with carcinoma cell
lines. GA733 precipitated 37kD, 30kD and 29kD proteins
under reducing conditions, and only one 30kD protein
under non-reducing conditions. The immunoreactivity of
GA733 to malignant and normal tissue section varied greatly
from that of HEA125, as GA733 showed a substantial
heterogeneity in its staining of gastro-intestinal cancers,
many of which were not detected at all. Moreover, normal
colon mucosa was only reactive when located adjacent to
tumors. MAb 250-3.6, obtained after immunization with
HT-29 cells by Thompson and co-workers was shown to
detect major proteins of 25 and 27kD and possibly other
minor components (Thompson et al., 1983). In comparison
to HEA125, 250-3.6 exhibited a less broad reactivity720 G. MOLDENHAUER et al.
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Figure 6 Immunoperoxidase staining with HEA125 of
nitrocellulose dot blot of enzyme-treated HT-29 lysates (a-d) and
glycolipids isolated from colon carcinoma tissue (f): a, PBS
control; b, endoglycosidase F; c, endoglycosidase D; d,
neuraminidase; e, pronase E. Pronase E-treated HT-29 lysates (g)
and colon carcinoma glycolipids (h) stained with control mouse
MAb (HEA164) to Lewisa b carbohydrate antigens.
-c
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Figure 5 SDS-PAGE analysis under reducing conditions of
immunoprecipitates of HEA125 from HT-29 cells lysates. A,
molecular weight standards; B, non-digested precipitates; C, 2h
endoglycosidase F treatment of precipitates; D, overnight
endoglycosidase F treatment of precipitates; E, irrelevant control
MAb; arrowheads, minor band ofprecipitates.
towards epithelial cell lines and tissue sections, e.g., it failed
to bind to malignant and normal cells from breast or lung.
Monoclonal antibodies raised to different histotypes of
lung carcinoma were reported to recognize antigens of 31 kD
(Mulshine et al., 1983), 39 and 42kD (Okabe et al., 1984),
40kD (Varki et al., 1984) and again 40kD (Radosevich et
al., 1985; Lee et al., 1985), another MAb raised to mammary
carcinoma precipitates a 43 kD molecule (Edwards et al.,
1986). The reactivities of these antibodies with malignant cell
lines and with normal and malignant tissues have been
determined with varying accuracy. However, in addition to
the slight differences in molecular weights, the data on cell
line reactivity and immunohistochemistry clearly indicate
that these MAbs recognize antigens different from Egp34
because they show a considerably more restricted tissue
reactivity.
Undifferentiated large cell tumours often pose great
problems to the pathologist. Carcinomas, large cell
lymphomas, amelanotic melanomas, seminomas and
sometimes even sarcomas may come into question.
105 x binding sites/cell
Figure 7 Scatchard plot of 1251-HEA125 binding to HT-29
cells. Binding sites per cell were calculated provided a molar
ratio of 1.0 of Egp34 to labelled MAb HEA125.
Table III Detection of Egp34 in tumour cell
supernatants and lysates by radioimmunoassaya
Tumour cell supernatantsb Binding to HEA125
HT-29 30,828 + 587C
SW1116 27,817+ 1,018
WiDr 17,859+ 91
Raji 1,225+ 288
HSB-2 963+ 450
HL-60 1,553+ 165
Tumour cell lysatesd Dilution Binding to HEA125
HT-29 1:1 9,207+1,663
1:2 6,314+ 664
1:5 3,912+ 510
1:25 1,377+ 773
1:125 811+ 375
Raji 1:1 424+ 154
1:2 472+ 230
aSolid phase RIA using HEA125 as catcher
antibody and 1251-labelled rabbit antibodies to HT-29
cells as detector; blO times concentrated tumour cell
supernatants; ccpm+s.e.m of triplicate assay; dNP-40
lysates corresponding to 5 x 107 cellsml-, dilutions
with PBS.EPITHELIAL SURFACE GLYCOPROTEIN 721
Therefore, a reliable marker with specificity for a particular
lineage is desirable. In contrast to other antibodies that tend
to become unreactive with decreasing degree of tumour
differentiation (Edwards, 1985), HEA125 allows the
recognition of tumour cells of anaplastic, diffusely
infiltrating carcinomas. Hence, HEA125 may represent a
valuable tool for the distinction of carcinomas from tumours
of other lineages.
The strong surface expression of Egp34 allows the
separation of carcinoma cells from stromal cells in cell
sorting procedures. This could improve clonogenic tumour
cell assays which are employed for anti-tumour drug
sensitivity testing of individual tumours. Furthermore, an
immunoscintigraphic detection of tumour masses is
conceivable. Metastatic deposits of carcinomas in the liver
seem to be suitable targets since the surrounding hepatic
parenchyma should not bind the antibody. In a pilot study,
131I-labelled HEA125 is currently applied for the detection
of liver metastases in colon cancer patients.
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